MSC 1 - Northern Biologics
Latest Information Update: 25 Oct 2021
At a glance
- Originator Vall d-Hebron Research Institute
- Developer Northern Biologics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Leukaemia inhibitory factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for phase-I development in Cancer(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Spain (Parenteral)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Canada (IV)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV)